Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease

2 Jan 2025

Abstract excerpt

Chronic kidney disease affects ~10% of people worldwide and there are no disease modifying therapeutics that address the underlying cause of any form of kidney disease. Genome wide association studies have identified the G1 and G2 variants in the apolipoprotein L1 (APOL1) gene as major contributors to a subtype of proteinuric kidney disease now referred to as APOL1-mediated kidney disease (AMKD). We hypothesized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
Share to Renal Diseases and Glomerulopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39747090
DOI: 10.1038/s41467-024-55408-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney diseasePMID 39747090Read ↗

Small Molecule APOL1 Inhibitors as a Precision Medicine Approach for APOL1-mediated Kidney DiseaseSemantic proximity Read ↗

APOL1 nephropathy - a population genetics success story.Semantic proximity Read ↗

Molecular Mechanisms of APOL1-Associated Kidney Disease.Semantic proximity Read ↗

APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.Semantic proximity Read ↗

APOL1-associated kidney disease: modulators of the genotype-phenotype relationship.Semantic proximity Read ↗

Apolipoprotein L1 nephropathies: 2017 in review.Semantic proximity Read ↗

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.Semantic proximity Read ↗

APOL1 and kidney cell functionSemantic proximity Read ↗

The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.Semantic proximity Read ↗

Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.Semantic proximity Read ↗

Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicitySemantic proximity Read ↗

APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.